ECS

AMSC Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Outlook

Retrieved on: 
星期三, 五月 29, 2024
Growth, AMSC, GAAP, ECS, Grid

AYER, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- AMSC (Nasdaq: AMSC), a leading system provider of megawatt-scale power resiliency solutions that orchestrate the rhythm and harmony of power on the grid™, and that protect and expand the capability and resiliency of our Navy’s fleet, today reported financial results for its fourth quarter and fiscal year ended March 31, 2024 ("fiscal 2023").

Key Points: 
  • Revenues for the fourth quarter of fiscal 2023 were $42.0 million compared with $31.7 million for the same period of fiscal 2022.
  • AMSC’s net loss for the fourth quarter of fiscal 2023 was $1.6 million, or $0.05 per share, compared to net loss of $6.9 million, or $0.25 per share, for the same period of fiscal 2022.
  • The Company’s non-GAAP net income for the fourth quarter of fiscal 2023 was $1.9 million, or $0.06 per share, compared with a non-GAAP net loss of $7.8 million, or $0.28 per share, in the same period of fiscal 2022.
  • AMSC reported a net loss for fiscal 2023 of $11.1 million, or $0.37 per share, compared to a net loss of $35.0 million, or $1.26 per share in fiscal 2022.

ECS Names Kelly Demaitre Senior Vice President of Human Capital

Retrieved on: 
星期二, 五月 28, 2024
Data Management, Technology, Manufacturing, Security, Research, Artificial Intelligence, Defense, Contracts, Internet, Engineering, Science, Human Capital, Growth, Karsun, CACI, ECS, Human resources, Management

ECS , a leader in advanced technology, science, and engineering solutions, has named Kelly Demaitre senior vice president of Human Capital.

Key Points: 
  • ECS , a leader in advanced technology, science, and engineering solutions, has named Kelly Demaitre senior vice president of Human Capital.
  • As a member of ECS’ executive leadership team, Demaitre will oversee multiple ECS departments and programs, from Human Resources and Recruiting to career- and culture-building initiatives.
  • “I’m thrilled that Kelly is joining our leadership team,” said John Heneghan , president of ECS.
  • Demaitre has also served as chief human resources officer at Dovel Technologies and held multiple leadership roles at CACI International, including senior vice president of Human Resources.

Vital Farms’ Egg Central Station Earns Prestigious LEED® Gold Certification Recognizing Environmental Excellence in Manufacturing Standards

Retrieved on: 
星期三, 五月 8, 2024
Food safety, USGBC, ECS, Animal, Heart, Biophysical environment, Vital, Food industry, Certification, Platinum, LEED, Music recording certification, Growth

LEED® (Leadership in Energy and Environmental Design) is the U.S. Green Building Council ’s (USGBC) internationally recognized green building rating system and a symbol of excellence in environmental stewardship.

Key Points: 
  • LEED® (Leadership in Energy and Environmental Design) is the U.S. Green Building Council ’s (USGBC) internationally recognized green building rating system and a symbol of excellence in environmental stewardship.
  • “When we designed Egg Central Station and its expansion, we challenged ourselves to build a facility that fully embodies our purpose—to improve the lives of people, animals, and planet,” said Russell Diez-Canseco, President & CEO, Vital Farms.
  • Egg Central Station notably scored extra points in the “Innovation in Design” section for crewmember education, green cleaning protocols, and pest management.
  • Learn more about Vital Farms’ various impact efforts in the company’s 2024 Impact Report and discover more about LEED® Certification and USGBC: here .

Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers

Retrieved on: 
星期三, 五月 8, 2024
OMEGA, Cell, ECS, Gene, Society, Gene expression, Messenger, Therapy, Vaccine

Additional OMEGA platform capabilities demonstrated, including reversible downregulation and multiplexed upregulation of gene expression

Key Points: 
  • Additional OMEGA platform capabilities demonstrated, including reversible downregulation and multiplexed upregulation of gene expression
    CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the presentation of new preclinical data demonstrating durable and tunable bidirectional regulation of gene expression in cellular models at the pre-transcriptional level at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, taking place in Baltimore, Maryland, May 7 – 11.
  • “These exciting new data underscore the versatile capabilities and power of our OMEGA platform,” said Thomas McCauley, Ph.D., Chief Scientific Officer of Omega Therapeutics.
  • “We have demonstrated preclinically that we can prospectively engineer epigenomic controllers to predictably and durably upregulate gene expression across a diverse range of gene types, including turning on inactivated genes, augmenting the expression of genes with low baseline expression levels, and leveraging existing genomic regulatory processes to boost expression.
  • Additionally, simultaneous targeting of two regulatory elements for the same gene with two separate ECs yielded a synergistic effect, more than doubling expression compared to single element targeting.

ESS Tech, Inc. Announces First Quarter 2024 Financial Results

Retrieved on: 
星期二, 五月 7, 2024
Other Energy, Utilities, Batteries, Environment, Alternative Energy, Energy, Technology, Green Technology, Momentum, EDT, Safety, Reuters, Sacramento Municipal Utility District, IEEE, ESS, EW, ECS, Kilowatt-hour, TECO Energy, SMUD, Portland General Electric, Amsterdam Airport Schiphol, Telephone, Growth, Interest, Renewable energy

ESS Tech, Inc. (“ESS,” “ESS, Inc.” or the “Company”) (NYSE: GWH), a leading manufacturer of long-duration energy storage systems for commercial and utility-scale applications, today announced financial results for its first quarter ended March 31, 2024.

Key Points: 
  • ESS Tech, Inc. (“ESS,” “ESS, Inc.” or the “Company”) (NYSE: GWH), a leading manufacturer of long-duration energy storage systems for commercial and utility-scale applications, today announced financial results for its first quarter ended March 31, 2024.
  • We have completed all of our performance, safety and regulatory tests for our first EC and are operating the unit right now.
  • ESS will hold a conference call on Tuesday, May 7, 2024 at 5:00 p.m. EDT to discuss financial results for its first quarter 2024 ended March 31, 2024.
  • A live webcast of the conference call will be available on ESS’ Investor Relations website at http://investors.essinc.com/ .

Xcelerate Solutions Welcomes Vivek Malhotra as President

Retrieved on: 
星期三, 五月 8, 2024
Titan, Electrical engineering, Johns Hopkins University, ECS, Computer science, VMD, Knox College, Culture, Growth

MCLEAN, Va., May 8, 2024 /PRNewswire/ -- Xcelerate Solutions ("Xcelerate"), a leading defense and national security company, today announced Vivek Malhotra as President.

Key Points: 
  • MCLEAN, Va., May 8, 2024 /PRNewswire/ -- Xcelerate Solutions ("Xcelerate"), a leading defense and national security company, today announced Vivek Malhotra as President.
  • Xcelerate recently merged with VMD Corp ("VMD") where Mr. Malhotra was a cofounder and served as President.
  • "I am beyond excited to welcome Vivek to our leadership team," said Mark Drever, CEO and founding partner of Xcelerate.
  • Incoming Xcelerate President, Vivek Malhotra added, "Xcelerate has amazing potential to contribute to the security landscape of our clients.

New Study Demonstrates Avenda Health's Unfold AI to Better Predict Focal Therapy Success by 77% Percent as Compared to Standard Methods

Retrieved on: 
星期三, 五月 8, 2024
UCLA, FDA, ECS, AI, American Urological Association, Health, Unfold, MD, PSA, Doctor of Philosophy, Prostate cancer, GG5, Patient, GG1, Physician, AUA, MRI, Biopsy, UCLA Health, Neoplasm, GG, Quality of life, Cryotherapy, Medical imaging

CULVER CITY, Calif., May 8, 2024 /PRNewswire/ -- Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, unveils the results of a new UCLA study examining the role of AI in identifying tumor margins and predicting the efficacy of focal therapy treatments. The study titled "Software to Determine Extent of Tumor Margins in Focal Therapy," was presented at the 2024 American Urological Association's (AUA) annual meeting by Wayne Brisbane, MD, assistant professor at UCLA Health. It demonstrated that Unfold AI, Avenda Health's AI-powered cancer mapping technology, was a better predictor of focal therapy success than other factors, including the size or grade of the tumor.

Key Points: 
  • It demonstrated that Unfold AI , Avenda Health's AI-powered cancer mapping technology, was a better predictor of focal therapy success than other factors, including the size or grade of the tumor.
  • In the study, FDA-cleared Unfold AI technology was retrospectively applied to 118 previously untreated men undergoing hemi-gland cryotherapy for prostate cancer ablation.
  • MRI-guided biopsies, both targeted and systematic, were performed before cryotherapy and six months after cryotherapy to assess treatment outcomes.
  • "This more comprehensive approach enhances our ability to predict treatment outcomes and tailor interventions effectively to individual patient needs."

Unisys Announces 1Q24 Results

Retrieved on: 
星期二, 五月 7, 2024
Sale, ECS, Unisys, Depreciation, Yoy, TCV, DP, DWS, Public expenditure, Tax, Eastern Time Zone, Modern, GAAP, Constant

BLUE BELL, Pa., May 7, 2024 /PRNewswire/ -- Unisys Corporation (NYSE: UIS) reported financial results for the first quarter of 2024.

Key Points: 
  • Unisys will hold a conference call with the financial community on Wednesday, May 8 at 8 a.m. Eastern Time to discuss the results of the first quarter of 2024.
  • The live, listen-only webcast, as well as the accompanying presentation materials, can be accessed on the Unisys Investor Website at www.unisys.com/investor .
  • In addition, domestic callers can dial 1-844-695-5518 and international callers can dial 1-412-902-6749 and provide the following conference passcode: Unisys Corporation Call.
  • A webcast replay will be available on the Unisys Investor Website shortly following the conference call.

GENESIS REVEALS U.S. PRICING FOR NEW 2025 GV80 SUV

Retrieved on: 
星期五, 五月 3, 2024
Slate, Nappa, ECS, V6, MSRP, Map, Isle, OTA, MLA, Active suspension, Genesis, AWD, Smartphone, OLED, Third, Shades of gray, Alloy, USB

Redesigned GV80 elevates the driving experience for both drivers and passengers with new enhancements, design updates and technologies

Key Points: 
  • Redesigned GV80 elevates the driving experience for both drivers and passengers with new enhancements, design updates and technologies
    FOUNTAIN VALLEY, Calif., May 3, 2024 /PRNewswire/ -- Genesis today announced U.S. pricing for the new 2025 GV80 SUV.
  • "The 2025 GV80 brings a new level of elevated cabin experience to the Genesis SUV lineup, making all occupants feel like honored guests," said Claudia Marquez, chief operating officer of Genesis Motor North America.
  • The 2025 GV80 2.5T is available in four additional trims: 2.5T AWD, 2.5T Select AWD, 2.5T Advanced AWD and 2.5T Prestige AWD.
  • The 2025 GV80 2.5T Standard AWD and 2025 GV80 2.5T Select AWD will be available this summer.

Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting

Retrieved on: 
星期二, 四月 23, 2024
Poster, Cell, ECS, Gene, Society, Gene expression, Messenger, Annual general meeting, Therapy

CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced it will present a poster at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place in Baltimore, MD, May 7 – 11, 2024.

Key Points: 
  • CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced it will present a poster at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place in Baltimore, MD, May 7 – 11, 2024.
  • The poster will feature new preclinical data that demonstrate the ability of Omega's programmable epigenomic controllers (ECs) to pre-transcriptionally upregulate gene expression across a diverse set of genes, offering a broad range of potential therapeutic applications.
  • Details for the poster presentation are as follows:
    The poster will be made available on the Omega website at https://omegatherapeutics.com/science/publications/ at the same time as the presentation.